Compliance · The complete guide

510(k) vs PMA

TL;DR

510(k) vs PMA — the two principal FDA premarket routes for medical devices. 510(k) is a notification of substantial equivalence to a legally marketed predicate (Class II default, ~3,000 clearances per year). PMA is an independent demonstration of safety and effectiveness (Class III, ~50 approvals per year). The route is set by classification, not by the sponsor's preference; the choice determines fee, timeline, evidence depth, post-market obligations and labelling rights.

Reviewed May 30, 2026· By V5 Ultimate compliance team· 2,100 words · ~10 min read

01The core difference — comparison vs proof

510(k) and PMA answer different questions. A 510(k) submission asks 'is this device at least as safe and effective as a legally marketed predicate?' — a comparative question answered by a substantial-equivalence (SE) argument plus performance data. A PMA submission asks 'is this device safe and effective for its intended use?' — an absolute question answered by an independent body of clinical and non-clinical evidence sufficient to support that conclusion on its own.

Classification under 21 CFR 860 determines which question applies. Class II devices use 510(k); Class III devices use PMA. The choice is not a sponsor preference — a sponsor cannot elect to 'just do a 510(k)' on a Class III device, and conversely cannot inflate a Class II submission into a PMA. Misclassification arguments belong in the 513(g) Request for Information or De Novo process, not in the premarket route choice.

02Side by side

	510(k)	PMA
Statutory basis	FD&C Act §510(k), 21 CFR 807 Subpart E.	FD&C Act §515, 21 CFR 814.
Device class	Class II default; some Class I that retain 510(k).	Class III (life-supporting, life-sustaining, or unreasonable risk).
Question answered	Substantial equivalence to a legally marketed predicate.	Reasonable assurance of safety and effectiveness on the device's own merits.
Clinical data	Required in roughly 10% of submissions; non-clinical/bench performance is enough for most.	Almost always required — usually a pivotal IDE study with predefined endpoints and statistical analysis plan.
MDUFA V review goal	90 FDA days to SE/NSE decision; real-world median ~177 calendar days.	180 FDA days; real-world median 300+ calendar days, with multi-cycle review common.
User fee (FY26 estimate)	~$24,335 standard / ~$6,083 small business.	~$540,783 standard / ~$135,196 small business.
Submission format	eSTAR mandatory since 1 Oct 2023.	Modular PMA or traditional PMA; eCopy required.
Advisory panel	Almost never.	Common for novel Class III devices.
Manufacturing inspection	Not part of the submission decision (compliance covered by routine QSR/QMSR inspection).	Pre-approval inspection (PAI) is routine and can hold approval.
Post-market obligations	MDR, post-approval studies rare; condition-of-approval studies for some 522 postmarket surveillance orders.	Annual reports, post-approval studies frequently mandated, PMA supplements required for design changes.
Labelling rights	'510(k) cleared' — cannot claim 'FDA-approved'.	'FDA-approved' is the correct term.
Change-management route	New 510(k) under the 2017 decision tree; Special 510(k) for design changes verifiable through V&V.	PMA supplement (Panel Track, 180-day, Real-Time, Special, 30-day Notice, etc.) — type chosen by change category.

03How the evidence differs

A 510(k) performance-data section is built around the predicate comparison. Bench testing demonstrates equivalence on performance parameters relevant to the device type — flow rate, accuracy, mechanical strength, dose precision, electrical safety, biocompatibility per ISO 10993. Software follows IEC 62304 documentation. Clinical data is included only when bench data cannot fully address a different technological characteristic or different question of safety and effectiveness.

A PMA is built around a pivotal clinical study, almost always conducted under an Investigational Device Exemption (IDE) per 21 CFR 812. The study has a defined hypothesis, endpoints, comparator (often historical or active control), sample-size justification, statistical analysis plan, and an FDA-agreed final analysis. The submission integrates the clinical evidence with full non-clinical performance data, design-controls evidence, manufacturing process descriptions, and labelling. PMA submissions routinely run to 50,000+ pages.

04Timeline and cost reality

Headline MDUFA goals tell only part of the story. A typical Class II 510(k) takes 6–9 months from preparation start to clearance, with most of the time in pre-submission work, not FDA review. A typical PMA takes 4–6 years from IDE planning to approval, dominated by clinical-study conduct. Cost ratios reflect the evidence asymmetry: a 510(k) programme often runs $200K–$1M all-in; a PMA programme runs $20M–$100M+ when clinical study costs are included.

The user-fee gap is intentional — Congress set PMA fees high to fund the deeper review. Small-business waivers help, but the dominant cost driver for both routes is the development and study expense, not the fee.

05When each route applies — and the third option

Use 510(k) when the device is Class II (or Class I requiring 510(k)) and a predicate exists with matching intended use. Use PMA when the device is Class III — life-supporting, life-sustaining, of substantial importance in preventing impairment of human health, or presenting potential unreasonable risk. Use the De Novo classification request when the device is novel and there is no predicate, but the sponsor believes the device is low or moderate risk and special controls would suffice. A successful De Novo creates a new generic device type that future devices can use as a 510(k) predicate.

An HDE (Humanitarian Device Exemption) is a fourth route limited to devices for rare conditions (defined as affecting or being manifested in not more than 8,000 individuals per year in the US after the 2016 update); the safety/effectiveness bar is lower than PMA but the device must demonstrate probable benefit.

06Common mistakes — and how to avoid them

Stretching a 510(k) by combining a primary predicate with a 'reference device' to bridge intended-use gaps. FDA explicitly rejects the split-predicate; reference devices may support specific technological characteristics only.
Treating a PMA supplement as a small effort. Even a 30-day Notice for a manufacturing-site change requires substantial documentation; an approved-supplement-required change can trigger another six-month review cycle.
Skipping the pre-submission (Q-Sub) meeting. For any non-trivial 510(k) or any PMA, a Q-Sub on predicate strategy, study design or testing plan saves a multi-month AI cycle later.
Labelling a 510(k)-cleared device as 'FDA-approved' in marketing. This is a misbranding violation under section 502 and a recurring source of FTC and FDA letters.
Failing to plan for the PMA pre-approval inspection. PAI failures hold final approval until the site is acceptable; QMS rigour through the IDE phase is the prevention.

Frequently asked questions

Q.Can a device move from PMA to 510(k)?+

Only if FDA reclassifies the device type from Class III to Class II under section 513(e). This has happened for AEDs and several other legacy Class III categories, but is a multi-year FDA initiative, not a sponsor election.

Q.Is the De Novo route faster than PMA?+

Almost always — De Novo MDUFA V goal is 150 FDA days vs PMA's 180. The bigger difference is evidence depth: De Novo can often rely on bench and limited clinical data, whereas PMA expects a pivotal study.

Q.Does a 510(k) require a clinical trial?+

Usually not. About 10% of 510(k) submissions include clinical data, typically when a different technological characteristic raises a question that bench testing cannot fully answer.

Q.Is a PMA supplement the same as a new PMA?+

No — a supplement modifies an existing approved PMA. Supplement types range from a 30-day Notice (for manufacturing changes) to a Panel-Track supplement (for major design or indication changes), with very different evidence and timeline expectations.

Q.What does 'PMA approvable letter' mean?+

FDA's signal that the PMA can be approved subject to specific labelling, manufacturing or post-approval-study conditions. It is not the final approval order — the approval letter follows once conditions are met.

Q.Can the same device have a 510(k) and a PMA?+

A device has one premarket route per indication. A device cleared via 510(k) for one indication can require a PMA for a higher-risk indication, but each indication is its own regulatory entity.